Slate Therapeutics: Pioneering Long-Acting Drug Delivery for CRS, Neurology & Obesity:
At Slate Therapeutics, we are revolutionizing long-acting drug delivery with innovative sinus-to-brain and oral extended-release technologies. Our proprietary platform enables weeks-to-months of controlled drug release, transforming treatment for chronic rhinosinusitis (CRS), neurological disorders, and metabolic diseases—including obesity.
Our Drug Delivery Platforms
🔹 Sinus Drug Delivery: Our proprietary formulation provides over 45 days of sustained release when placed in the sinus, offering a game-changing approach for CRS and direct-to-brain drug delivery via the olfactory pathway.
🔹 Long-Acting Oral Drug Delivery (Obesity & Metabolic Disease): Expanding beyond CRS, we are developing an extended-release oral platform designed to enhance drug efficacy, reduce dosing frequency, and improve patient adherence. Our initial focus is on obesity and metabolic syndromes, addressing the rapidly growing demand for next-generation weight loss treatments.
Company Details
- Employees
- 2
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://slatetherapeutics.com/
- Keywords
- Tel aviv.
Slate Therapeutics Questions
Slate Therapeutics's website is https://slatetherapeutics.com/
Slate Therapeutics's LinkedIn profile is https://www.linkedin.com/company/slatetx
Slate Therapeutics has
2 employees.
View email and phone details for 2
employees at Slate Therapeutics.
Slate Therapeutics's industry is
Biotechnology Research
Slate Therapeutics's top competitors are
Gisha Shona - גישה שונה,
Jaguahr Therapeutics,
Israel Disruptive Technologies®,
Ub Therapeutics,
I Derm Pharma,
Kal-Quote,
Pepvic,
Barcode Nanotech,
In2 By Virility Medical,
Protekt Therapeutics.
Slate Therapeutics's categories are Biotechnology Research
